terms of agreement, page-40

Hi skyrocketer,

"Would GSK offer 49% of the future drug profit to ISIS? Of course not. 49% is a much larger deal than an upfront fee of a few millions. In fact, if given a choice, I would take the 49% shares of the drug than a few million upfront fee."

Fair enough... careful on that slippery slope ;)

Under the terms of the agreement, which covers up to six programmes, Isis will receive an upfront $35 million payment from GSK... and is eligible to receive on average up to $20 million in milestones per programme up to Phase 2 proof of concept (PoC). GSK will have the option to license compounds at PoC, and will be responsible for all further development and commercialisation. Isis will be eligible to receive license fees and milestone payments, totaling nearly $1.5 billion, in the event all six programmes are successfully developed for one or more indications and commercialised through to pre-agreed sales targets. In addition Isis will receive up to double-digit royalties on sales, from any product that is successfully commercialised."

It's all good skyrocketer - don't be concerned about what I, anyone else, or even our market thinks. Imho, there are three things most relevant to ANP holders over the short term...

This, this and this ;)